Spots Global Cancer Trial Database for solid tumours

Every month we try and update this database with for solid tumours cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors	NCT00732420	Solid Tumours	topotecan pazopanib	18 Years -	GlaxoSmithKline
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	NCT05555251	HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast...	BI-1607 BI-1607 Trastuzumab	18 Years -	BioInvent International AB
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies	NCT05417594	Advanced Solid ...	AZD9574 Temozolomide [11C]AZ1419 339... Datopotamab Der... Trastuzumab Der...	18 Years - 130 Years	AstraZeneca
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors	NCT00743067	Solid Tumours	GSK1363089 (for...	18 Years -	GlaxoSmithKline
A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR	NCT02687386	Solid Tumours CNS Tumours	Mitoxantrone pa...	2 Years - 21 Years	Sydney Children's Hospitals Network
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors	NCT03266159	Solid Tumours	GSK525762 Besyl... Trametinib tabl...	18 Years -	GlaxoSmithKline
Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours	NCT02042781	Advanced Solid ...	PG545	18 Years -	Zucero Pty Ltd
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma	NCT00695448	Solid Tumours	GSK1059615	18 Years -	GlaxoSmithKline
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class	NCT03036228	Cancer	Karonudib	18 Years - 75 Years	Thomas Helleday Foundation
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test	NCT04529122	Solid Tumours		18 Years -	Hoffmann-La Roche
An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer	NCT01266954	Solid Tumours	GSK2141795	18 Years - 85 Years	GlaxoSmithKline
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors	NCT00742131	Solid Tumours	GSK1363089	18 Years -	GlaxoSmithKline
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours	NCT01921140	Solid Tumours	Olaparib tablet... Pharmacokinetic... Dietary Fasted Dietary High Fa...	18 Years - 130 Years	AstraZeneca
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors	NCT01956669	Solid Tumours	Pazopanib	1 Year - 18 Years	Novartis
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours	NCT02215850	Solid Tumours	SLC-0111	18 Years -	Welichem Biotech Inc.
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects	NCT01340040	Cancer Advanced Solid ...	MEDI-573	18 Years -	AstraZeneca
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers	NCT01974349	Solid Tumours	selumetinib (or...	18 Years - 45 Years	AstraZeneca
Study of XIAP Antisense for Advanced Cancers	NCT00385775	Advanced Cancer	AEG35156	18 Years -	Aegera Therapeutics
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours	NCT01921140	Solid Tumours	Olaparib tablet... Pharmacokinetic... Dietary Fasted Dietary High Fa...	18 Years - 130 Years	AstraZeneca
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma	NCT00687622	Solid Tumours	GSK1120212	18 Years -	GlaxoSmithKline
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)	NCT01928940	Solid Tumours	dabrafenib trametinib	20 Years -	GlaxoSmithKline
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours	NCT01900028	Solid Tumours	Pharmacokinetic... Olaparib tablet... Itraconazole	18 Years - 130 Years	AstraZeneca
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment	NCT01894243	Solid Tumours	Olaparib tablet...	18 Years - 130 Years	AstraZeneca
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects	NCT02063204	Solid Tumours	selumetinib	18 Years -	AstraZeneca
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test	NCT04529122	Solid Tumours		18 Years -	Hoffmann-La Roche
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors	NCT00136578	Solid Tumours	SB-715992 carboplatin	18 Years -	GlaxoSmithKline
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment	NCT02161770	Solid Tumours	AZD9291 tablet ... Pharmacokinetic... Pharmacokinetic...	18 Years - 99 Years	AstraZeneca
A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR	NCT02687386	Solid Tumours CNS Tumours	Mitoxantrone pa...	2 Years - 21 Years	Sydney Children's Hospitals Network
Tissue Collection Framework To Improve Outcomes In Solid Tumours	NCT03572192	Solid Tumours		18 Years -	Queen Mary University of London
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours	NCT03415100	Solid Tumours	CAR-NK cells ta...	18 Years - 70 Years	The Third Affiliated Hospital of Guangzhou Medical University
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma	NCT01767454	Solid Tumours	Dabrafenib Trametinib Ipilimumab	18 Years -	GlaxoSmithKline
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors	NCT00743067	Solid Tumours	GSK1363089 (for...	18 Years -	GlaxoSmithKline
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors	NCT00742261	Solid Tumours	GSK1363089	18 Years -	GlaxoSmithKline
Dose-Escalation Study of GSK2126458	NCT00972686	Solid Tumours	GSK2126458	18 Years -	GlaxoSmithKline
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors	NCT01956669	Solid Tumours	Pazopanib	1 Year - 18 Years	Novartis
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours	NCT04504669	Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ...	AZD8701 Durvalumab	18 Years - 101 Years	AstraZeneca
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function	NCT01894256	Solid Tumours	Olaparib tablet...	18 Years - 75 Years	AstraZeneca
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	NCT05555251	HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast...	BI-1607 BI-1607 Trastuzumab	18 Years -	BioInvent International AB
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour	NCT00878111	Solid Tumors	NGR-hTNF	18 Years -	AGC Biologics S.p.A.
Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours	NCT02042781	Advanced Solid ...	PG545	18 Years -	Zucero Pty Ltd
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours	NCT04889599	Docetaxel Solid Tumours Bioequivalence	BH009 (Docetaxe... Docetaxel injec...	18 Years -	Zhuhai Beihai Biotech Co., Ltd
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours	NCT00566410	Neoplasms	Dichloroacetate	18 Years -	AHS Cancer Control Alberta
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function	NCT00483860	Solid Tumours	Topotecan	18 Years -	GlaxoSmithKline
A Phase I Trial of AZD3965 in Patients With Advanced Cancer	NCT01791595	Adult Solid Tum... Diffuse Large B... Burkitt Lymphom...	AZD3965 AZD3965 AZD3965 AZD3965 AZD3965 AZD3965 AZD3965	18 Years -	Cancer Research UK
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours	NCT01929603	Solid Tumours	Pharmacokinetic... Rifampicin Olaparib tablet...	18 Years - 99 Years	AstraZeneca
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma	NCT03702036	Solid Tumours	molibresib	16 Years -	GlaxoSmithKline
Dose-Escalation Study of GSK2126458	NCT00972686	Solid Tumours	GSK2126458	18 Years -	GlaxoSmithKline
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment	NCT01894243	Solid Tumours	Olaparib tablet...	18 Years - 130 Years	AstraZeneca
Phase I Trial of VS-6766 Alone and in Combination With Everolimus	NCT02407509	Solid Tumours Multiple Myelom... Lung Cancer Ovarian Cancer	VS-6766 Everolimus	18 Years -	Royal Marsden NHS Foundation Trust
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma	NCT00687622	Solid Tumours	GSK1120212	18 Years -	GlaxoSmithKline
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours	NCT02215850	Solid Tumours	SLC-0111	18 Years -	Welichem Biotech Inc.
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours	NCT01921140	Solid Tumours	Olaparib tablet... Pharmacokinetic... Dietary Fasted Dietary High Fa...	18 Years - 130 Years	AstraZeneca
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma	NCT03702036	Solid Tumours	molibresib	16 Years -	GlaxoSmithKline
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours	NCT01851265	Solid Tumours	Olaparib Dietary Fasted Dietary standar... Dietary High Fa...	18 Years - 130 Years	AstraZeneca
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours	NCT03315091	Solid Tumours	Treatment A - A... Treatment B - A...	18 Years - 99 Years	AstraZeneca
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine	NCT04179071	Solid Tumours	Savolitinib Famotidine	18 Years - 65 Years	AstraZeneca
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers	NCT05302037	Cancer Malignancy Refractory Canc... Relapsed Cancer	Allogeneic NKG2...	21 Years -	CytoMed Therapeutics Pte Ltd
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers	NCT02056392	Solid Tumours	Selumetinib Moxifloxacin selumetinib pla...	18 Years - 45 Years	AstraZeneca
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers	NCT01931761	Solid Tumours	[C14] selumetin...	50 Years - 65 Years	AstraZeneca
AZD1152 in Patients With Advanced Solid Malignancies-Study 3	NCT00497679	Solid Tumours	AZD1152	18 Years -	AstraZeneca
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour	NCT00778128	Solid Tumors	CP-4126 Gemcitabine	18 Years -	Clavis Pharma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours	NCT02343718	Recurrent Lymph... Refractory Lymp... Solid Tumours Central Nervous...	Vinblastine Temsirolimus	1 Year - 18 Years	Canadian Cancer Trials Group
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects	NCT01340040	Cancer Advanced Solid ...	MEDI-573	18 Years -	AstraZeneca
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer	NCT03150056	Solid Tumours	GSK525762 Abiraterone Enzalutamide Prednisone	18 Years -	GlaxoSmithKline
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours	NCT01792310	Glioma Other Solid Tum...	LAM561	18 Years -	Laminar Pharmaceuticals
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology	NCT01626547	Chemotherapy-in... Solid Tumours Malignant Lymph... Multiple Myelom...		18 Years -	Hospira, now a wholly owned subsidiary of Pfizer
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers	NCT02093728	Solid Tumours	selumetinib itraconazole itraconazole selumetinib selumetinib fluconazole fluconazole selumetinib	18 Years - 45 Years	AstraZeneca
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors	NCT00742261	Solid Tumours	GSK1363089	18 Years -	GlaxoSmithKline
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class	NCT03036228	Cancer	Karonudib	18 Years - 75 Years	Thomas Helleday Foundation
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours	NCT01851265	Solid Tumours	Olaparib Dietary Fasted Dietary standar... Dietary High Fa...	18 Years - 130 Years	AstraZeneca
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers	NCT02056392	Solid Tumours	Selumetinib Moxifloxacin selumetinib pla...	18 Years - 45 Years	AstraZeneca
CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors	NCT02094560	Advanced Endsta...	CAP7.1	-	CellAct Pharma GmbH
TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients	NCT02492477	Adjuvant Chemot... Solid Tumours Port-A-Cath	evaluation of P... blocking with M... restoration of ...	18 Years - 90 Years	Krankenhaus Barmherzige Schwestern Linz
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects	NCT02063204	Solid Tumours	selumetinib	18 Years -	AstraZeneca
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations	NCT01948297	Solid Tumours	Debio1347 (CH51...	18 Years -	Debiopharm International SA
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma	NCT00687622	Solid Tumours	GSK1120212	18 Years -	GlaxoSmithKline
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers	NCT02046850	Solid Tumours	selumetinib rifampicin selumetinib rifampicin	18 Years - 45 Years	AstraZeneca
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy	NCT01798056	Herpes Zoster Herpes Zoster V...	GSK 1437173A Placebo	18 Years -	GlaxoSmithKline
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers	NCT02046850	Solid Tumours	selumetinib rifampicin selumetinib rifampicin	18 Years - 45 Years	AstraZeneca
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient	NCT01213160	Cancer Advanced Solid ...	AZD4547	25 Years - 150 Years	AstraZeneca

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: